Literature DB >> 1937916

Selective impairment of T lymphocyte activation following contact sensitization with oxazolone.

I Kimber1, J R Foster, D Baker, J L Turk.   

Abstract

We have previously reported that topical exposure of mice to oxazolone results in the appearance of regulatory mechanisms which markedly depress lymph node cell (LNC) proliferative responses to subsequent challenge with the same chemical. In the present study, we have sought to identify the cellular targets for such immunoregulation. Autoradiographic analyses revealed that although pre-exposure to oxazolone caused a substantial reduction of paracortical hyperplasia following challenge, the frequency of proliferating cells in lymphoid follicles was slightly increased. That B lymphocyte responses are unaffected by oxazolone-induced immunoregulation was confirmed by investigation of anti-hapten antibody formation by draining LNC. Challenge with oxazolone resulted in an accelerated antibody response in mice previously exposed to the same chemical. These data reveal that the active immunoregulation induced following sensitization with oxazolone is selective for T lymphocytes. Evidence is presented that CD4+ and CD8+ T lymphocytes possess equivalent sensitivity to these mechanisms.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1937916     DOI: 10.1159/000235419

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  3 in total

1.  Regulation of contact hypersensitivity by interleukin 10.

Authors:  T A Ferguson; P Dube; T S Griffith
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

2.  Low zone tolerance to contact allergens in mice: a functional role for CD8+ T helper type 2 cells.

Authors:  K Steinbrink; C Sorg; E Macher
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

3.  Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4.

Authors:  M Boirivant; I J Fuss; A Chu; W Strober
Journal:  J Exp Med       Date:  1998-11-16       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.